Alexis Edwards

Apr 27, 2023 | mdpi.com | Donald J. Alcendor |Patricia Matthews-Juarez |Duane L Smoot |Alexis Edwards

Abstract:The COVID-19 Omicron variant and its subvariants are now the dominant variants circulating in the US. Therefore, the original COVID-19 vaccine cannot offer full protection. Instead, vaccines that target the spike proteins of the Omicron variants are warranted. Hence, the FDA recommended the development of a bivalent booster. Unfortunately, despite the safety and immunogenicity of the Omicron bivalent boosters from Pfizer and Moderna, uptake in the US has been poor.